Colon Cancer Treatment - Response Genetics, Inc. to Present Multiple Studies at the 2008 - MSN MoneyCentral
Response Genetics, Inc. to Present Multiple Studies at the 2008 - MSN MoneyCentral
Response Genetics, Inc. RGDX will announce the results of studies that support the validity of using the molecular markers, excision repair cross-complementing factor 1 (ERCC1) and thymidylate synthase (TS) to help guide the selection of chemotherapy
‘Stand Up to Cancer’ - Chicago Tribune
ABC, CBS and NBC have set aside a prime-time hour on the Friday after Labor Day to simulcast a fundraiser for cancer research. “Stand Up to Cancer” on Sept. 5 will feature musical performances and celebrity appeals, although no guests were
Response Genetics, Inc. to Announce Pancreatic, Colon and Gastric - MSN MoneyCentral
Response Genetics, Inc. RGDX will announce the results of studies in pancreatic cancer, colon cancer and gastric cancer that identify novel biomarkers and genetic profile patterns that are predictive of therapeutic response. Results of these studies
Merck KGaA’s Erbitux Drug May Get Edge on Avastin (Update3) - Bloomberg
May 29 (Bloomberg) — A single gene may help Merck KGaA and ImClone Systems Inc. find which patients are best treated with their Erbitux cancer drug, helping gain an edge over Roche Holding AG and add 600 million euros ($938 million) in sales. Merck
Bristol to buy cancer expert Kosan for $235 mln - Forbes
NEW YORK (Reuters) - Bristol-Myers Squibb Co (nyse: BMY - news - people ) will acquire Kosan Biosciences Inc (nasdaq: KOSN - news - people ) for about $235 million to boost its presence in oncology, the companies said Thursday. At $5.50 per share